BioCentury | Jun 10, 2019
Distillery Therapeutics

Recombinant DAG1 for influenza

...INDICATION: Influenza virus Mouse studies suggest the N-terminal domain of the lung extracellular matrix receptor DAG1...
...infection. In a mouse model of influenza A virus infection, intranasal administration of the recombinant DAG1...
...could include testing the recombinant domain in additional models of influenza A virus infection. TARGET/MARKER/PATHWAY: Dystroglycan 1 (DAG1)...
BioCentury | Apr 27, 2018
Clinical News

DelMar reports Phase II data for VAL-083 in recurrent GBM

DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) reported data from 22 evaluable patients with recurrent glioblastoma multiforme (GBM) in a Phase II trial showing that VAL-083 (dianhydrogalactitol) led to stable disease as a best response in seven patients....
BioCentury | Sep 15, 2017
Clinical News

DelMar starts Phase II of VAL-083 for MGMT-unmethylated GBM

DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) began a Phase II trial of VAL-083 to treat newly diagnosed O6-alkylguanine alkyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM). The open-label, Chinese trial will enroll 20-30 patients in sequential dose-escalation cohorts to receive...
BioCentury | Sep 1, 2017
Finance

Armo's China network

Chinese investors in Armo BioSciences Inc. 's $67 million series C-1 round could help the Redwood City, Calif., company establish local partnerships and bring its lead cancer therapy to the China market. Qiming Venture Partners...
BioCentury | Sep 1, 2017
Financial News

Armo raises $67M series C-1 round

On Aug. 29, Armo BioSciences Inc. (Redwood City, Calif.) raised $67 million in an untranched series C-1 round led by Qiming Venture Partners. Fellow new investors Decheng Capital, Sequoia Capital, Quan Capital and RTW Investments...
BioCentury | Aug 29, 2017
Financial News

Armo raises $67M series C-1 round

Armo BioSciences Inc. (Redwood City, Calif.) raised $67 million in an untranched series C-1 round led by Qiming Venture Partners. Fellow new investors Decheng Capital, Sequoia Capital, Quan Capital and RTW Investments also participated, along...
BioCentury | Jan 27, 2017
Clinical News

VAL-083: Ph II started

DelMar began an open-label, U.S. Phase II trial to evaluate 40 mg/m 2 IV VAL-083 on days 1-3 of each 21-day cycle for up to 12 cycles in about 48 patients with O6-alkylguanine alkyltransferase (MGMT)-unmethylated,...
BioCentury | Nov 11, 2016
Company News

HEC, TaiGen deal

TaiGen’s TaiGen BioPharmaceuticals Co. subsidiary and HEC’s YiChang HEC ChangJiang Pharmaceutical Co. Ltd. (HKSE:1558, Gongguan, China) will establish an unnamed newco in China to develop and commercialize antiviral agents to treat chronic HCV infection. HEC...
BioCentury | Oct 31, 2016
Company News

TaiGen, HEC launch cross-strait newco for HCV combo

TaiGen Biopharmaceuticals Holdings Ltd. (TPex:4157) and the YiChang HEC ChangJiang Pharmaceutical Co. Ltd. (HKSE:1558) subsidiary of HEC Pharm Group (Dongguan, China) launched a newco that intends to develop HCV therapies for Greater China. The partners...
BioCentury | Feb 15, 2016
Financial News

Armo BioSciences completes venture financing

Armo BioSciences Inc. , Redwood City, Calif. Business: Cancer, Cardiovascular, Inflammation Date completed: 2016-02-10 Type: Venture financing Raised: $50 million Investors: Kleiner Perkins Caufield & Byers ; OrbiMed Advisors; DAG Ventures; NanoDimension; HBM Healthcare Investments; GV;...
Items per page:
1 - 10 of 55